Imfinzi Approved in US for High-Risk Bladder Cancer
Imfinzi Approved in the US as First Immunotherapy Combo for High-Risk Bladder Cancer
AstraZeneca's Imfinzi (durvalumab) has been approved in the United States as the first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).
This approval marks a significant milestone, offering a new treatment option that leverages the immune system to fight cancer cells more effectively than standard therapies.
The combination therapy aims to reduce the risk of disease progression and improve patients' quality of life. Consult your healthcare provider for more information.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…